Related Experiment Video

Updated: Jun 22, 2026

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
07:42

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

Antifungal prophylaxis with micafungin in patients treated for childhood cancer

Shigenori Kusuki1, Yoshiko Hashii, Hisao Yoshida

  • 1Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.

Pediatric Blood & Cancer
|June 18, 2009
PubMed
Abstract

Insights

Prophylactic micafungin effectively prevented invasive fungal infections (IFIs) in pediatric patients undergoing chemotherapy or hematopoietic stem cell transplantation (HSCT). This antifungal agent demonstrated good tolerability and safety in neutropenic children.

Area of Science:

  • Mycology
  • Pediatric Oncology
  • Hematology

Background:

  • Invasive fungal infections (IFIs) are a significant cause of mortality in neutropenic patients undergoing chemotherapy or hematopoietic stem cell transplantation (HSCT).
  • Micafungin possesses broad-spectrum antifungal activity against Aspergillus and Candida species, making it a potential prophylactic agent.
  • Pediatric neutropenic patients undergoing chemotherapy or HSCT are at high risk for IFIs.

Purpose of the Study:

  • To evaluate the efficacy of prophylactic micafungin in preventing IFIs.
  • To assess the safety and tolerability of micafungin prophylaxis in pediatric neutropenic patients.
  • To determine the treatment success rate of micafungin in preventing IFIs during chemotherapy and HSCT.

Main Methods:

  • Retrospective study of 40 pediatric patients receiving micafungin (3 mg/kg/day) intravenously.
  • Analysis of 131 patient-cycles post-chemotherapy and 15 patient-cycles post-HSCT.
  • Median neutropenia and prophylaxis duration of 13 days (chemotherapy) and 23 days (HSCT).

Main Results:

  • High treatment success rates observed: 93.9% after chemotherapy and 80.0% after HSCT.
  • Only one case of proven or probable IFI documented, occurring after HSCT.
  • No adverse events were attributed to micafungin prophylaxis, indicating good tolerability.

Conclusions:

  • Prophylactic micafungin appears to be a safe and well-tolerated option for preventing IFIs in pediatric neutropenic patients.
  • Micafungin demonstrates potential efficacy in reducing the incidence of IFIs in this vulnerable patient population.
  • Further prospective studies may be warranted to confirm these findings.

More Related Videos

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus12:29

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus

Published on: April 19, 2017

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...